

### REMARKS

Applicants wish to thank the Examiner for the courtesy extended to Applicants' representatives in discussing this application by telephone. As discussed during the interview, the amendment to Claim 1 does not materially change the scope of the claim since the claimed monoclonal antibodies are novel, and therefore patentable, regardless of an intended use. Claims 28-31 are redrafted as independent claims, without changing the scope of the claims. No new matter has been added herewith. Accordingly, entry of the amendments is respectfully requested.

#### No Disclaimers or Disavowals

Although the present communication may include alterations to the application or claims, or characterizations of claim scope or referenced art, Applicant is not conceding in this application that previously pending claims are not patentable over the cited references. Rather, any alterations or characterizations are being made to facilitate expeditious prosecution of this application. Applicant reserves the right to pursue at a later date any previously pending or other broader or narrower claims that capture any subject matter supported by the present disclosure, including subject matter found to be specifically disclaimed herein or by any prior prosecution. Accordingly, reviewers of this or any parent, child or related prosecution history shall not reasonably infer that Applicant has made any disclaimers or disavowals of any subject matter supported by the present application.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: March 10, 2009

By: 

Raymond D. Smith  
Registration No. 55,634  
Agent of Record  
Customer No. 20995  
(949) 760-0404